Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Single-arm, Open-label, Multi-center Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GLR2037 in Patients With Metastatic Prostate Cancer

NCT07468396 is registered in ClinicalTrials.gov with Gan & Lee Pharmaceuticals. as lead sponsor.

NCT NCT07468396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07468396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Single-arm, Open-label, Multi-center Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GLR2037 in Patients With Metastatic Prostate Cancer
Lead sponsor
Gan & Lee Pharmaceuticals.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 30, 2026
Completion date
April 30, 2033
Enrollment
65 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer